Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 4, 2015, Pages 395-404

  Koh, Wui Jin ^a   Greer, Benjamin E ^a   Abu Rustum, Nadeem R ^b   Apte, Sachin M ^c   Campos, Susana M ^d   Cho, Kathleen R ^e   Chu, Christina ^f   Cohn, David ^g   Crispens, Marta Ann ^h   Dorigo, Oliver ⁱ   Eifel, Patricia J ^j   Fisher, Christine M ^k   Frederick, Peter ^l   Gaffney, David K ^m   Han, Ernest ⁿ   Huh, Warner K ^o   Lurain, John R ^p   Mutch, David ^q   Fader, Amanda Nickles ^r   Remmenga, Steven W ^s   Reynolds, R Kevin ^e   Teng, Nelson ⁱ   Tillmanns, Todd ^t   Valea, Fidel A ^u   Yashar, Catheryn M ^v   McMillian, Nicole R ^w   Scavone, Jillian L ^w   more..

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Dana Farber   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

ⁱ STANFORD CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k University of Colorado Cancer Center   (United States)

^l ROSWELL PARK CANCER INSTITUTE   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^o UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^p NORTHWESTERN UNIVERSITY   (United States)

^q BARNES JEWISH HOSPITAL   (United States)

^r JOHNS HOPKINS UNIVERSITY   (United States)

^s UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^t UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^u DUKE CANCER INSTITUTE   (United States)

^v UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^w National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; TOPOTECAN; ANTINEOPLASTIC AGENT;

ACCREDITATION; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CONSENSUS; CONTINUING EDUCATION; DRUG APPROVAL; FEMALE; FERTILITY SPARING TREATMENT; FOOD AND DRUG ADMINISTRATION; GYNECOLOGIC SURGERY; HUMAN; INTERPERSONAL COMMUNICATION; LYMPH NODE DISSECTION; METASTASIS; PELVIS LYMPHADENECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CONIZATION; FERTILITY PRESERVATION; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FERTILITY PRESERVATION; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; UTERINE CERVICAL NEOPLASMS;

EID: 84928003857     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0055     Document Type: Review

References (65)

1. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-1488.
2. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315-324.
3. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007;38:189-197.
4. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177:469-479.
5. Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25:2975-2982.
6. Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer and World Health Organization; 2012. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed January 26, 2015.
7. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
8. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-2686.
9. Singh GK, Azuine RE, Siahpush M. Global inequalities in cervical cancer incidence and mortality are linked to deprivation, low socioeconomic status, and human development. Int J MCH and AIDS 2012;1:17-30.
10. Barnholtz-Sloan J, Patel N, Rollison D, et al. Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009;20:1129-1138.
11. Wang SS, Carreon JD, Gomez SL, Devesa SS. Cervical cancer incidence among 6 asian ethnic groups in the United States, 1996 through 2004. Cancer 2010;116:949-956.
12. Howe HL, Wu X, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006;107:1711-1742.
13. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005;103:1258-1264.
14. Singh GK. Rural-urban trends and patterns in cervical cancer mortality, incidence, stage, and survival in the United States, 1950-2008. J Community Health 2012;37:217-223.
15. Siegel R, Miller K, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin 2015;65:5-29.
16. SEER Program Stat Fact Sheets: Cancer of the Cervix Uteri. SEER Web site. Available at: http://seer.cancer.gov/statfacts/html/cervix.html. Accessed January 30, 2015.
17. Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981;48:899-903.
18. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113-3119.
19. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-4633.
20. Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw 2008;6:53-57.
21. Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008;110:67-71.
22. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-4655.
23. Tewari KS, Sill MW, Long HJ III, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-743.
24. Kitagawa R, Katsumata N, Ando M, et al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol 2012;125:307-311.
25. Kitagawa R, Katsumata N, Shibata T, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract 5006.
26. Penson RT, Huang H, Tewari KS, et al. Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a gynecologic oncology group study [abstract]. Presented at the European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, Netherlands.
27. National Cancer Institute. FDA approval for bevacizumab. 2014. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab. Accessed August 29, 2014.
28. Ramirez PT, Pareja R, Rendon GJ, et al. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? Gynecol Oncol 2014;132:254-259.
29. Cormier B, Diaz JP, Shih K, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol 2011;122:275-280.
30. Lecuru F, Mathevet P, Querleu D, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol 2011;29:1686-1691.
31. Altgassen C, Hertel H, Brandstadt A, et al. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol 2008;26:2943-2951.
32. Bats AS, Buenerd A, Querleu D, et al. Diagnostic value of intraoperative examination of sentinel lymph node in early cervical cancer: a prospective, multicenter study. Gynecol Oncol 2011;123:230-235.
33. Bats AS, Mathevet P, Buenerd A, et al. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. Ann Surg Oncol 2013;20:413-422.
34. Cibula D, Abu-Rustum NR, Dusek L, et al. Bilateral ultrastaging of sentinel lymph node in cervical cancer: lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol 2012;127:462-466.
35. Cibula D, Abu-Rustum NR, Dusek L, et al. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol Oncol 2012;124:496-501.
36. Fader AN, Edwards RP, Cost M, et al. Sentinel lymph node biopsy in early-stage cervical cancer: utility of intraoperative versus postoperative assessment. Gynecol Oncol 2008;111:13-17.
37. Lecuru F, Bats A, Mathevet P, et al. Impact of sentinel lymph node biopsy on staging of early cervical cancer: results of a prospective, multicenter study [abstract]. J Clin Oncol 2009;27(Suppl 18):Abstract CRA5506.
38. Slama J, Dundr P, Dusek L, Cibula D. High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer. Gynecol Oncol 2013;129:384-388.
39. van de Lande J, Torrenga B, Raijmakers PGHM, et al. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol 2007;106:604-613.
40. Andikyan V, Khoury-Collado F, Denesopolis J, et al. Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: is less enough? Int J Gynecol Cancer 2014;24:113-117.
41. Wu Y, Li Z, Wu H, Yu J. Sentinel lymph node biopsy in cervical cancer: a meta-analysis. Mol Clin Oncol 2013;1:1025-1030.
42. Eiriksson LR, Covens A. Sentinel lymph node mapping in cervical cancer: the future? BJOG 2012;119:129-133.
43. Darlin L, Persson J, Bossmar T, et al. The sentinel node concept in early cervical cancer performs well in tumors smaller than 2 cm. Gynecol Oncol 2010;117:266-269.
44. Ueki M, Okamoto Y, Misaki O, et al. Conservative therapy for microinvasive carcinoma of the uterine cervix. Gynecol Oncol 1994;53:109-113.
45. Al-Kalbani M, McVeigh G, Nagar H, McCluggage WG. Do FIGO stage IA and small (
46. Webb JC, Key CR, Qualls CR, Smith HO. Population-based study of microinvasive adenocarcinoma of the uterine cervix. Obstet Gynecol 2001;97:701-706.
47. Sevin BU, Nadji M, Averette HE, et al. Microinvasive carcinoma of the cervix. Cancer 1992;70:2121-2128.
48. Wright JD, NathavithArana R, Lewin SN, et al. Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol 2010;115:585-590.
49. Dargent D, Martin X, Sacchetoni A, Mathevet P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 2000;88:1877-1882.
50. Beiner ME, Covens A. Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer. Nat Clin Pract Oncol 2007;4:353-361.
51. Park JY, Joo WD, Chang SJ, et al. Long-term outcomes after fertility-sparing laparoscopic radical trachelectomy in young women with early-stage cervical cancer: an Asan Gynecologic Cancer Group (AGCG) study. J Surg Oncol 2014;110:252-257.
52. Gizzo S, Ancona E, Saccardi C, et al. Radical trachelectomy: the first step of fertility preservation in young women with cervical cancer (review). Oncol Rep 2013;30:2545-2554.
53. Raju SK, Papadopoulos AJ, Montalto SA, et al. Fertility-sparing surgery for early cervical cancer-approach to less radical surgery. Int J Gynecol Cancer 2012;22:311-317.
54. Abu-Rustum NR, Sonoda Y. Fertility-sparing surgery in early-stage cervical cancer: indications and applications. J Natl Compr Canc Netw 2010;8:1435-1438.
55. Diaz JP, Sonoda Y, Leitao MM, et al. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol 2008;111:255-260.
56. Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 2011;121:290-297.
57. Lanowska M, Mangler M, Speiser D, et al. Radical vaginal trachelectomy after laparoscopic staging and neoadjuvant chemotherapy in women with early-stage cervical cancer over 2 cm: oncologic, fertility, and neonatal outcome in a series of 20 patients. Int J Gynecol Cancer 2014;24:586-593.
58. Wethington SL, Sonoda Y, Park KJ, et al. Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. Int J Gynecol Cancer 2013;23:1092-1098.
59. Lintner B, Saso S, Tarnai L, et al. Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter. Int J Gynecol Cancer 2013;23:1065-1070.
60. Abu-Rustum NR, Sonoda Y, Black D, et al. Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol 2006;103:807-813.
61. Cao DY, Yang JX, Wu XH, et al. Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China. Br J Cancer 2013;109:2778-2782.
62. Einstein MH, Park KJ, Sonoda Y, et al. Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes. Gynecol Oncol 2009;112:73-77.
63. Wethington SL, Cibula D, Duska LR, et al. An international series on abdominal radical trachelectomy: 101 patients and 28 pregnancies. Int J Gynecol Cancer 2012;22:1251-1257.
64. Pareja R, Rendon GJ, Sanz-Lomana CM, et al. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review. Gynecol Oncol 2013;131:77-82.
65. Abu-Rustum NR, Tal MN, DeLair D, et al. Radical abdominal trachelectomy for stage IB1 cervical cancer at 15-week gestation. Gynecol Oncol 2010;116:151-152.